Drug Profile
APN 1701
Alternative Names: [18F]-APN-1701; APN-1701; PBB3 tau PET tracerLatest Information Update: 22 Sep 2022
Price :
$50
*
At a glance
- Originator APRINOIA Therapeutics
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Alzheimer's disease
- Preclinical Neurodegenerative disorders
Most Recent Events
- 31 Jul 2022 Pharmacokinetics data from clinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2022) .
- 31 Jul 2022 Clinical trials in Alzheimer's disease (Diagnosis) in Taiwan (Parenteral)
- 07 Jul 2022 Preclinical trials in Alzheimer's disease (Diagnosis) in Taiwan (Parenteral) (APRINOIA Therapeutics pipeline, July 2022)